Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients

This invention discloses method of treating or inhibiting cancer in a human having at least one of an Exon 19 del E746-A750 and/or an Exon 21 point mutation comprising administering to said human gefitinib and/or iressa alone or in combination with other cytotoxic agents or chemotherapeutic agents a...

Full description

Saved in:
Bibliographic Details
Main Authors QUINN, SUSAN E, LUNDBERG, ANTE (BILL), ZACHARCHUK, CHARLES M, MARTINS, PATRICIA, GREENBERGER, LEE
Format Patent
LanguageChinese
English
Published 16.05.2007
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention discloses method of treating or inhibiting cancer in a human having at least one of an Exon 19 del E746-A750 and/or an Exon 21 point mutation comprising administering to said human gefitinib and/or iressa alone or in combination with other cytotoxic agents or chemotherapeutic agents and an effective amount of EGFR kinase inhibitor.
Bibliography:Application Number: TW200695112747